Nebivolol for the treatment of heart failure

American Journal of Health-System Pharmacy

Volumn 68, Issue 10, 2011, Pages 879-886

  Dery, Allison S ^a   Hamilton, Leslie A ^b   Starr, Jessica A ^b  

^a SENTARA HEALTHCARE   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Cardiac drugs; Dosage; Drug interactions; Heart failure; Mechanism of action; Metabolism; Mortality; Nebivolol; Pharmacokinetics; Toxicity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 3 ADRENERGIC RECEPTOR; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CIMETIDINE; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOXETINE; FUROSEMIDE; LOOP DIURETIC AGENT; METOPROLOL; NEBIVOLOL; PLACEBO; PROPAFENONE; PROPRANOLOL; QUINIDINE; RITONAVIR;

ADULT DISEASE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CONGESTIVE CARDIOMYOPATHY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HOSPITAL READMISSION; HUMAN; HYPERTENSION; HYPOTENSION; MUSCULOSKELETAL PAIN; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASODILATATION; WEAKNESS;

EID: 79957633729     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100309     Document Type: Review

References (25)

1. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53:e1-90.
2. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation. 2009; 119:e21-181.
3. Parker RB, Rodgers JE, Cavallari LH. Heart failure. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill; 2008:173-216.
4. Braunwald E. Heart failure and cor pulmonale. In: Kasper DL, Fauci AS, Longo DL et al., eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2004.
5. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation. 1996; 94:2285-96.
6. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111:2837-49. (Pubitemid 40791557)
7. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-235.
8. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119:1997-2016.
9. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29:2388-442.
10. Mangrella M, Rossi F, Fici F. Pharmacology of nebivolol. Pharmacol Res. 1998; 38:419-31. (Pubitemid 29002262)
11. Drugdex. Nebivolol. www.thomsonhc. com (accessed 2010 May 28).
12. Bystolic (nebivolol) package insert. St. Louis: Forest Pharmaceuticals, Inc.; 2010.
13. 1-blocker. J Clin Pharmacol. 2008; 48:225-39.
14. Munzel T, Gori T. Nebivolol: the somewhat-different β-adrenergic receptor blocker. J Am Coll Cardiol. 2009; 54:1491-9.
15. Lefebvre J, Poirier L, Poirier P et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol. 2006; 63:575-82.
16. Wisenbaugh T, Katz I, Davis J et al. Long-term (3 months) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993; 21:1094-100. (Pubitemid 23106181)
17. Brehm BR, Wolf SC, Gorner S et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail. 2002; 4:757-63. (Pubitemid 35403085)
18. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26:215-25. (Pubitemid 40222359)
19. Ghio S, Magrini G, Serio A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular function: results of the SENIORS echocardiographic substudy. Eur Heart J. 2006; 27:562-8.
20. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail. 2005; 7:631-9. (Pubitemid 40732997)
21. Patrianakos AP, Parthenakis FI, Mavrakis HE et al. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy: a 12-month study. Am Heart J. 2005; 150:985.e9-18.
22. Lombardo RM, Reina C, Abrignani MG et al. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs. 2006; 6:259-63. (Pubitemid 44285135)
23. Dobre D, van Veldhuisen DJ, Mordenti G et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J. 2007; 154:109-15. (Pubitemid 46920477)
24. Uhlir O, Dvorak I, Gregor P et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail. 1997; 3:271-6. (Pubitemid 127674859)
25. Food and Drug Administration. Meeting of the Cardiovascular and Renal Drugs Advisory Committee. www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ ucm192863.htm (accessed 2010 May 28).